Prochymal™ Clinical Trial Information for the Treatment of Acute GVHD

Acute Graft versus Host Disease (GVHD) is a potentially life threatening complication that arises in approximately 50% of all patients who receive a hematopoietic stem cell transplant (HSCT). Allogeneic HSCT are used for the treatment of diseases including hematological malignancies, certain forms of anemia, and immunological deficiencies. The transplant is derived from donated bone marrow, cord blood, or peripheral blood. GVHD occurs when immune cells in the donated cell population attack the recipient cells because the recipient cells are seen as “foreign.” Organs that are mainly affected by the immunological attack are the gastrointestinal (GI) tract, skin, and liver.

GVHD occurs in up to 50% of patients, and symptoms generally appear within 100 days of transplant. GVHD may affect the digestive system (GI tract), skin, liver and other body systems.

Your Options

It is vitally important that we continue to find new effective ways to treat individuals who develop GVHD. By participating in clinical trials, you can make an invaluable contribution to others experiencing this devastating disease.

Phase III trial for Steroid-refractory Acute GVHD is currently enrolling patients

Phase III trial for newly diagnosed Acute GVHD is currently enrolling patients

Phase II results of Acute GVHD trial

Phase II Treatment-refractory Acute GVHD trial